Comment on:Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD:results of real-life ELU study

摘要

Dear Editor,The study by Queguiner et al[1]compared the number of follow up visits and intravitreal injections in 33 patients with wet age-related macular degeneration(AMD)treated initially with ranibizumab(Lucentis;Genentech,Inc.,South San Francisco,CA,USA;phase 1)and then switched to aflibercept(Eylea;Regeneron Pharmaceuticals Inc.